Limits...
Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.

Xie Y, Peng Z, Shi M, Ji M, Guo H, Shi H - Mol Med Rep (2014)

Bottom Line: A bromodeoxyuridine ELISA kit was used to analyze the effects of metformin, SB203580, a p38 MAPK inhibitor, and metformin combined with SB203580, on the cell proliferation of SKOV3/DDP cisplatin‑resistant ovarian cancer cells.Metformin combined with SB203580 significantly enhanced the sensitivity of SKOV3/DDP cells to cisplatin.Metformin, combined with the p38 MAPK inhibitor, significantly increased the sensitivity of SKOV3/DDP cells to cisplatin treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.

ABSTRACT
The aim of the present study was to determine the effects of metformin, combined with a p38 mitogen‑activated protein kinase (MAPK) inhibitor, on the sensitivity of cisplatin‑resistant ovarian cancer to cisplatin. The expression and distribution of phosphorylated p38 MAPK (P‑p38 MAPK) was confirmed in drug‑resistant and primary ovarian cancer tissues by immunohistochemistry and western blotting. A bromodeoxyuridine ELISA kit was used to analyze the effects of metformin, SB203580, a p38 MAPK inhibitor, and metformin combined with SB203580, on the cell proliferation of SKOV3/DDP cisplatin‑resistant ovarian cancer cells. The protein expression of P‑p38 MAPK was significantly higher in cisplatin‑resistant ovarian cancer, as compared with the primary ovarian cancer tissues. Metformin combined with SB203580 significantly enhanced the sensitivity of SKOV3/DDP cells to cisplatin. In conclusion, the p38 MAPK signaling pathway may be associated with cisplatin‑resistant ovarian cancer. Metformin, combined with the p38 MAPK inhibitor, significantly increased the sensitivity of SKOV3/DDP cells to cisplatin treatment.

Show MeSH

Related in: MedlinePlus

Expression of phosphorylated (P)-p38 mitogen activated protein kinase (MAPK) in chemotherapy-resistant and primary epithelial ovarian cancer tissues. The control group consisted of ovarian cancer tissues following initial cytoreductive surgery. The drug-resistant group was composed of chemotherapy-resistant epithelial ovarian cancer tissues. The levels of P-p38 MAPK and p38 MAPK proteins were detected by western blotting. GAPDH was used as an internal loading control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214348&req=5

f2-mmr-10-05-2346: Expression of phosphorylated (P)-p38 mitogen activated protein kinase (MAPK) in chemotherapy-resistant and primary epithelial ovarian cancer tissues. The control group consisted of ovarian cancer tissues following initial cytoreductive surgery. The drug-resistant group was composed of chemotherapy-resistant epithelial ovarian cancer tissues. The levels of P-p38 MAPK and p38 MAPK proteins were detected by western blotting. GAPDH was used as an internal loading control.

Mentions: The relative expression of P-p38 MAPK protein in chemotherapy-resistant EOC tissues was significantly increased, as compared with the primary ovarian cancer tissues (Fig. 2), as determined by western blotting.


Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.

Xie Y, Peng Z, Shi M, Ji M, Guo H, Shi H - Mol Med Rep (2014)

Expression of phosphorylated (P)-p38 mitogen activated protein kinase (MAPK) in chemotherapy-resistant and primary epithelial ovarian cancer tissues. The control group consisted of ovarian cancer tissues following initial cytoreductive surgery. The drug-resistant group was composed of chemotherapy-resistant epithelial ovarian cancer tissues. The levels of P-p38 MAPK and p38 MAPK proteins were detected by western blotting. GAPDH was used as an internal loading control.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214348&req=5

f2-mmr-10-05-2346: Expression of phosphorylated (P)-p38 mitogen activated protein kinase (MAPK) in chemotherapy-resistant and primary epithelial ovarian cancer tissues. The control group consisted of ovarian cancer tissues following initial cytoreductive surgery. The drug-resistant group was composed of chemotherapy-resistant epithelial ovarian cancer tissues. The levels of P-p38 MAPK and p38 MAPK proteins were detected by western blotting. GAPDH was used as an internal loading control.
Mentions: The relative expression of P-p38 MAPK protein in chemotherapy-resistant EOC tissues was significantly increased, as compared with the primary ovarian cancer tissues (Fig. 2), as determined by western blotting.

Bottom Line: A bromodeoxyuridine ELISA kit was used to analyze the effects of metformin, SB203580, a p38 MAPK inhibitor, and metformin combined with SB203580, on the cell proliferation of SKOV3/DDP cisplatin‑resistant ovarian cancer cells.Metformin combined with SB203580 significantly enhanced the sensitivity of SKOV3/DDP cells to cisplatin.Metformin, combined with the p38 MAPK inhibitor, significantly increased the sensitivity of SKOV3/DDP cells to cisplatin treatment.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.

ABSTRACT
The aim of the present study was to determine the effects of metformin, combined with a p38 mitogen‑activated protein kinase (MAPK) inhibitor, on the sensitivity of cisplatin‑resistant ovarian cancer to cisplatin. The expression and distribution of phosphorylated p38 MAPK (P‑p38 MAPK) was confirmed in drug‑resistant and primary ovarian cancer tissues by immunohistochemistry and western blotting. A bromodeoxyuridine ELISA kit was used to analyze the effects of metformin, SB203580, a p38 MAPK inhibitor, and metformin combined with SB203580, on the cell proliferation of SKOV3/DDP cisplatin‑resistant ovarian cancer cells. The protein expression of P‑p38 MAPK was significantly higher in cisplatin‑resistant ovarian cancer, as compared with the primary ovarian cancer tissues. Metformin combined with SB203580 significantly enhanced the sensitivity of SKOV3/DDP cells to cisplatin. In conclusion, the p38 MAPK signaling pathway may be associated with cisplatin‑resistant ovarian cancer. Metformin, combined with the p38 MAPK inhibitor, significantly increased the sensitivity of SKOV3/DDP cells to cisplatin treatment.

Show MeSH
Related in: MedlinePlus